X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dr. Reddys with IPCA Labs - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs IPCA LABS - Comparison Results

DR. REDDYS LAB    Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB IPCA LABS DR. REDDYS LAB/
IPCA LABS
 
P/E (TTM) x 31.5 28.1 112.2% View Chart
P/BV x 3.4 3.3 101.4% View Chart
Dividend Yield % 0.8 0.1 553.7%  

Financials

 DR. REDDYS LAB   IPCA LABS
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-18
IPCA LABS
Mar-18
DR. REDDYS LAB/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs2,788695 400.9%   
Low Rs1,902400 475.4%   
Sales per share (Unadj.) Rs860.8260.2 330.8%  
Earnings per share (Unadj.) Rs57.119.0 300.8%  
Cash flow per share (Unadj.) Rs122.033.1 369.1%  
Dividends per share (Unadj.) Rs20.001.00 2,000.0%  
Dividend yield (eoy) %0.90.2 467.2%  
Book value per share (Unadj.) Rs757.7213.0 355.7%  
Shares outstanding (eoy) m165.91126.20 131.5%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.72.1 129.4%   
Avg P/E ratio x41.128.9 142.3%  
P/CF ratio (eoy) x19.216.6 116.0%  
Price / Book Value ratio x3.12.6 120.4%  
Dividend payout %35.05.3 664.9%   
Avg Mkt Cap Rs m389,03469,120 562.8%   
No. of employees `00023.513.3 177.5%   
Total wages/salary Rs m32,1497,359 436.9%   
Avg. sales/employee Rs Th6,070.82,477.4 245.0%   
Avg. wages/employee Rs Th1,366.6555.2 246.1%   
Avg. net profit/employee Rs Th402.5180.6 222.8%   
INCOME DATA
Net Sales Rs m142,81032,836 434.9%  
Other income Rs m1,552418 371.3%   
Total revenues Rs m144,36233,254 434.1%   
Gross profit Rs m23,5124,505 521.9%  
Depreciation Rs m10,7721,777 606.1%   
Interest Rs m788240 328.1%   
Profit before tax Rs m13,5042,905 464.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m3440-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m4,380511 857.0%   
Profit after tax Rs m9,4682,394 395.5%  
Gross profit margin %16.513.7 120.0%  
Effective tax rate %32.417.6 184.4%   
Net profit margin %6.67.3 90.9%  
BALANCE SHEET DATA
Current assets Rs m104,98419,455 539.6%   
Current liabilities Rs m68,93810,076 684.2%   
Net working cap to sales %25.228.6 88.4%  
Current ratio x1.51.9 78.9%  
Inventory Days Days7498 76.0%  
Debtors Days Days10467 154.7%  
Net fixed assets Rs m104,38520,260 515.2%   
Share capital Rs m830252 328.8%   
"Free" reserves Rs m124,88626,633 468.9%   
Net worth Rs m125,71626,886 467.6%   
Long term debt Rs m25,0892,340 1,072.1%   
Total assets Rs m225,44341,173 547.6%  
Interest coverage x18.113.1 138.5%   
Debt to equity ratio x0.20.1 229.3%  
Sales to assets ratio x0.60.8 79.4%   
Return on assets %4.56.4 71.1%  
Return on equity %7.58.9 84.6%  
Return on capital %9.710.8 90.2%  
Exports to sales %047.6 0.0%   
Imports to sales %014.9 0.0%   
Exports (fob) Rs mNA15,642 0.0%   
Imports (cif) Rs mNA4,884 0.0%   
Fx inflow Rs m72,62315,642 464.3%   
Fx outflow Rs m18,9164,884 387.3%   
Net fx Rs m53,70710,759 499.2%   
CASH FLOW
From Operations Rs m18,0303,411 528.5%  
From Investments Rs m-14,883-1,354 1,099.2%  
From Financial Activity Rs m-4,440-1,304 340.5%  
Net Cashflow Rs m-1,236753 -164.1%  

Share Holding

Indian Promoters % 25.5 45.9 55.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.4 11.4 47.4%  
FIIs % 35.3 25.3 139.5%  
ADR/GDR % 18.5 0.0 -  
Free float % 15.3 17.4 87.9%  
Shareholders   75,885 36,892 205.7%  
Pledged promoter(s) holding % 0.0 2.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   FDC LTD.  UNICHEM LAB  WYETH LTD  AJANTA PHARMA  ALEMBIC LTD  

Compare DR. REDDYS LAB With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 275 Points; Realty and Banking Stocks Witness Selling(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

IPCA LABS Announces Quarterly Results (1QFY19); Net Profit Down 423.6% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, IPCA LABS has posted a net profit of Rs 655 m (down 423.6% YoY). Sales on the other hand came in at Rs 9 bn (up 19.8% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

DR. REDDYS LAB Announces Quarterly Results (1QFY19); Net Profit Up 614.9% (Quarterly Result Update)

Jul 27, 2018 | Updated on Jul 27, 2018

For the quarter ended June 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 614.9% YoY). Sales on the other hand came in at Rs 37 bn (up 12.1% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Sep 21, 2018 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB 8-QTR ANALYSIS

COMPARE DR. REDDYS LAB WITH

MARKET STATS